Sign in

    Dustin Scaringe

    Research Analyst at William Blair

    Dustin Scaringe is an Equity Research Analyst specializing in diagnostics and life sciences at William Blair, where he covers companies such as Veracyte and Aspira Women's Health. He began his career at Robert W. Baird & Co. as an Equity Research Analyst before joining William Blair in 2021, and previously held roles at IBM and JEB Capital Partners. Scaringe holds an undergraduate degree from the University of Notre Dame and is FINRA-registered with the CRD#: 7151885, though his registration is currently inactive. He is recognized for his in-depth sector knowledge and engagement with publicly traded diagnostic firms, frequently participating in earnings calls for covered companies.

    Dustin Scaringe's questions to AXDX leadership

    Dustin Scaringe's questions to AXDX leadership • Q4 2023

    Question

    Asked about the specific performance metrics for Wave to be released at ECCMID, the FDA approval timeline for the isolates menu following the initial gram-negative panel, and for guidance on company spending and cash burn expectations for the upcoming year.

    Answer

    The company plans to release Wave data at ECCMID, including metrics like essential agreement, categorical agreement, and time-to-result. The menu strategy post-gram-negative PBC is to focus on gram-positive PBC (expected approval in 2025), followed by gram-negative and gram-positive isolates. Significant cash burn reductions are expected, particularly in R&D (about $2M savings per quarter), as Wave moves into clinical trials, with Q4's spend serving as a good baseline for 2024 modeling.

    Ask Fintool Equity Research AI

    Dustin Scaringe's questions to AWH leadership

    Dustin Scaringe's questions to AWH leadership • Q3 2023

    Question

    Inquired about the launch timeline and success metrics for EndoCheck, confidence in the finalization of the CMS rule for OvaWatch and its impact on longitudinal monitoring pricing, the outlook for 2024 volume and ASP, and the company's cash burn and runway.

    Answer

    The company maintains its EndoCheck launch timeline for year-end with a broader rollout in Q1 2024. They are highly confident the CMS pricing for OvaWatch will be finalized and do not expect it to affect the longitudinal product. No guidance for 2024 was provided. The company reiterated its H2 2023 cash burn guidance and mentioned its focus on managing cash and exploring funding options, including existing equity lines.

    Ask Fintool Equity Research AI